Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Completed · Phase 2
Conditions studied: Adult Glioblastoma Multiforme
In brief
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 works in treating patients with recurrent glioblastoma multiforme.
Key facts
- Study ID
- NCT00895180
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 80
- Starts
- 2010-07-01
- Expected to finish
- 2014-03-04
- Last updated by the study team
- 2017-12-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UAB Comprehensive Cancer Center — Birmingham, Alabama, United States
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
- University of California San Francisco Medical Center — San Francisco, California, United States
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa, Florida, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
- Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
- University of Pittsburgh School of Medicine — Pittsburgh, Pennsylvania, United States
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.